Ligandrol vs Ostarine: What to Choose and for Whom
Ligandrol and ostarine are perhaps the only SARMs for which randomized studies in humans have been published. Because of this they are often presented as a "proven choice." The editorial team explains why the existence of several short studies does not make these substances suitable for independent use, for whom they were intended, and what legal paths lead to the same goals.
Why this pair seems like a "choice"
For most SARMs there is almost no data on effects in humans. Against this background, ligandrol (LGD-4033, VK5211) and ostarine (enobosarm) look "scientific": for them there are publications in peer-reviewed journals, with doses, duration, and results specified.
It is precisely this circumstance that is often used in advertising: "clinically studied." But between "was studied" and "proved safety for your use" there is a great distance. The studies lasted weeks, with carefully selected volunteers participating under constant medical monitoring.
Moreover, none of the studies ended in registration of the drug. Regulators did not recognize these molecules as medicines, and therefore did not approve any indications, doses, or contraindications.
Therefore the question "what to choose" for this pair, as for other SARMs, the editorial team reformulates: who could benefit in a medical context and how to achieve the same goals legally.
What the studies say and what they do not say
In the ligandrol study (Basaria et al., 2013) healthy young men took the substance for 21 days. Lean mass increased, but at the same time HDL and total testosterone decreased, and after discontinuation the indicators returned to baseline values.
In the phase II ostarine study (Dalton et al., 2011) elderly men and postmenopausal women took the substance for 12 weeks. Lean mass and a stair-climbing measure improved compared with placebo.
- The studies say:in the short term both substances increase lean mass in certain groups of people.
- The studies say:these effects are accompanied by changes in lipids and hormones.
- The studies do not say:what will happen with long-term use, repeated cycles, or combinations.
- The studies do not say:how products from the internet behave, whose composition often does not match the label (Van Wagoner et al., 2017).
In addition, the studies did not compare ligandrol and ostarine directly. Therefore any claims that one is "stronger" or "safer" have no clinical basis.
Target patients: how they are helped today
Ligandrol was developed for people with age-related muscle loss and for recovery after hip fracture, ostarine for elderly people and patients with cancer cachexia. These are real medical problems, and for them evidence-based solutions exist.
For sarcopenia, international clinical guidelines (Cruz-Jentoft et al., 2019, the EWGSOP2 consensus) emphasize strength training as the basis of treatment, together with nutritional assessment and sufficient protein intake.
For patients after hip fractures, early mobilization, rehabilitation, fall prevention, and treatment of osteoporosis prescribed by a doctor play a key role.
For oncology patients with cachexia, treatment is selected by a multidisciplinary team, including nutritional support. No SARM today is part of the standard treatment of these conditions, because they did not receive registration.
For whom SARMs are categorically unsuitable
| Group | Why |
|---|---|
| Athletes who undergo doping control | Both substances are in section S1.2 of the WADA list; ostarine is often detected in samples, in particular through contaminated supplements |
| Adolescents | Effect on the formation of the hormonal system |
| Women who are pregnant or planning pregnancy | Androgenic action, absence of safety data |
| Men planning to have children | Suppression of testosterone and gonadotropins |
| People with liver diseases | Cases of drug-induced liver injury have been described (Flores et al., 2020) |
| People with dyslipidemia or ischemic heart disease | Decrease in HDL |
For competitive athletes an additional factor is the long half-life of ligandrol, described in the study by Basaria and colleagues: the substance stays in the body longer.
People who take any prescription drugs must remember that there are practically no studies of interactions of SARMs with other drugs.
Finally, people prone to addictive behavior should know that the use of SARMs often becomes a "step" toward anabolic steroids.
Legal paths to the same goals
People turn to SARMs seeking three things: more muscle, more strength, less fat. For each of these goals there are evidence-based and legal tools.
| Goal | Evidence-based approach |
|---|---|
| Muscle mass growth | Strength training with progression, sufficient protein throughout the day, an energy surplus |
| Strength | A structured program, creatine monohydrate (Kreider et al., 2017) |
| Fat reduction | A moderate calorie deficit, maintaining strength training and protein |
| Recovery | Sleep, load management, nutrition |
The position of the International Society of Sports Nutrition on creatine (Kreider et al., 2017) summarizes dozens of studies that confirm its effectiveness and safety for healthy people - unlike SARMs.
Athletes should choose supplements with independent certification for the absence of prohibited substances.
If you have already taken SARMs, discuss it with a doctor and check liver tests, a lipid panel, and a hormonal profile.
Editorial conclusions
The existence of short clinical studies does not make ligandrol or ostarine a safe choice. These data describe weeks of controlled intake, not real practice.
The target groups for which these molecules were developed - elderly people, patients after fractures, cancer patients - today receive help through rehabilitation, training, nutrition, and registered medicines.
For healthy people and athletes the legal and evidence-based tools are training, nutrition, sleep, and trusted supplements.
We also recommend the articles "Ligandrol or Ostarine: what is the difference," "Ostarine vs RAD-140: what to choose and for whom," and a piece about creatine monohydrate.
References
- Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87–95.
- Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2(3):153–161.
- Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.
- Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017;318(20):2004–2010.
- Flores JE, Chitturi S, Walker S. Drug-induced liver injury by selective androgenic receptor modulators. Hepatol Commun. 2020;4(3):450–452.
- Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017;14:18.
- World Anti-Doping Agency. International Standard: Prohibited List. Montreal: WADA; 2025.
Andriy Melnyk
A strength-sports coach and author of programs for beginner and intermediate levels. Writes about training planning.
